Kixta Capsules in Singapore: Uses, Strengths & Side Effects

Kixta Capsules contain palbociclib, a targeted anticancer medicine used to treat certain types of advanced or metastatic breast cancer. It is prescribed for hormone receptor-positive (HR-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer, in combination with specific hormone therapies.

For patients and healthcare professionals in Singapore researching Kixta Capsules, understanding the active ingredient, approved indications and safety precautions is important. Palbociclib belongs to a class of medicines called cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. It works by blocking proteins involved in cell division, helping slow the growth of cancer cells.

Cordium Pharmaceuticals Pvt Ltd provides pharmaceutical product information to support informed enquiries from international healthcare and pharmaceutical trade audiences. Product availability, registration and supply eligibility should be confirmed before any commercial transaction.

Kixta Capsules Strengths

Kixta Capsules are available in the following strengths, according to published product information:

Kixta 75 mg Capsules

Kixta 100 mg Capsules

Kixta 125 mg Capsules

The prescribed strength depends on the patient's condition, treatment response, blood test results and tolerance to the medicine. Only an oncologist or other qualified healthcare professional should determine the appropriate dose.

Benefits and Uses of Kixta Capsules

Kixta Capsules are used as part of a prescribed treatment plan for certain patients with advanced or metastatic HR-positive, HER2-negative breast cancer.

Potential clinical benefits include:

Slowing cancer cell growth: Palbociclib inhibits CDK4 and CDK6 proteins involved in cell-cycle progression.

Supporting combination therapy: It can be used with an aromatase inhibitor as initial endocrine-based therapy or with fulvestrant following progression after endocrine therapy.

Helping manage disease progression: When appropriately prescribed with hormone therapy, it can help delay disease progression in eligible patients.

Treatment outcomes vary between individuals. Kixta Capsules are not suitable for every type of breast cancer and should not be considered a cure.

Kixta Capsules Side Effects

Like other anticancer medicines, Kixta Capsules may cause side effects. Commonly reported effects include:

Reduced white blood cell counts

Increased susceptibility to infections

Fatigue and weakness

Nausea or diarrhoea

Hair thinning or hair loss

Mouth sores

Anaemia

Reduced platelet counts and rash

Important safety warning: Fever, chills, unusual bleeding, unexplained bruising or signs of infection require prompt medical assessment. Seek urgent medical attention for severe breathing difficulties or other serious symptoms.

Regular blood tests are important during treatment. Patients should tell their healthcare team about all medicines and supplements they take, as well as any liver or kidney problems. Pregnancy and breastfeeding require particular medical attention because palbociclib may pose serious risks.

Frequently Asked Questions About Kixta Capsules

1. What are Kixta Capsules used for?

Kixta Capsules contain palbociclib and are used with specified hormone therapies for certain types of HR-positive, HER2-negative advanced or metastatic breast cancer.

2. What strengths are available?

Published product listings identify 75 mg, 100 mg and 125 mg strengths. Confirm the specific product and pack details with the authorised supplier.

3. How should Kixta Capsules be taken?

Follow the exact instructions provided by the prescribing oncologist and the applicable product leaflet. Do not change the dose or treatment schedule independently.

4. What are the main side effects?

Low blood cell counts, infection risk, fatigue, nausea, diarrhoea, hair loss and mouth sores are among the possible side effects.

5. Is Kixta available in Singapore?

Availability and registration of the specific Kixta brand must be verified with Singapore's Health Sciences Authority (HSA). Do not assume that registration of palbociclib or another brand confirms Kixta's approval.

Important Medical Disclaimer

This page is for general educational purposes only and does not replace professional medical advice, diagnosis or treatment. Kixta Capsules should be used only under appropriate medical supervision and in accordance with applicable local regulations.

About Cordium Pharmaceuticals Pvt Ltd: Contact the company for verified product specifications, documentation and pharmaceutical trade enquiries, subject to applicable Singapore registration, import and supply requirements.